ADALTA ORD
AdAlta inks major CAR-T deal for global development outside China
AdAlta (ASX:1AD) has secured exclusive rights to co-develop Shanghai Cell Therapy Group's BZDS1901 CAR-T therapy outside Greater China, a significant move validating its 'East-to-West' strategy and po
Market wrap: big banks send ASX into record territory
Australia’s big banks have pushed the ASX 200 to a record close of 7847 points after more signs of lower inflation in major economies caused a global relief rally. With interest rates now looking almost a certainty to fall in the big markets of the US, Europe and Australia, investors celebrated hard with a fresh […]
AdAlta’s AD-214 demonstrates safety and efficacy potential for fibrotic disease treatment
Top-line results from a Phase I extension study of AdAlta’s (ASX: 1AD) lead asset AD-214 in the treatment of fibrotic disease have established the safety, tolerability and bioavailability of a target dose for planned Phase II clinical studies. The results are reported to have also positively answered key questions from pharmaceutical partner companies in support […]
AdAlta completes patient recruitment for AD-214 study to treat debilitating diseases
Clinical stage drug discovery company AdAlta (ASX: 1AD) has completed the recruitment of healthy volunteers to its Phase I extension study of lead candidate AD-214 to treat debilitating and fatal scarring diseases including idiopathic pulmonary fibrosis (IPF). The study is designed to assess the safety and availability of multiple intravenous doses measuring 10 milligrams per […]